Cart
sales@molnova.com
PROTAC ERRα ligand 2
CAS No. 2306388-57-6
PROTAC ERRα ligand 2( —— )
Catalog No. M20565 CAS No. 2306388-57-6
PROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist( IC50 : 5.67 nM)
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 92 | In Stock |
|
| 5MG | 84 | In Stock |
|
| 10MG | 112 | In Stock |
|
| 25MG | 199 | In Stock |
|
| 50MG | 293 | In Stock |
|
| 100MG | 439 | In Stock |
|
| 200MG | 613 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePROTAC ERRα ligand 2
-
NoteResearch use only, not for human use.
-
Brief DescriptionPROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist( IC50 : 5.67 nM)
-
DescriptionPROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist( IC50 : 5.67 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorERRα
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2306388-57-6
-
Formula Weight445.31
-
Molecular FormulaC20H13F6NO4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (140.35 mM)
-
SMILESCOc1cc(\C=C(/C#N)C(O)=O)ccc1OCc1ccc(cc1C(F)(F)F)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Peng L Zhang Z Lei C et al. Identification of New Small-Molecule Inducers of Estrogen-Related Receptor alpha (ERRa) Degradation[J]. ACS Medicinal Chemistry Letters 2019 10(5).
molnova catalog
related products
-
GDC-0810
GDC-0810 (ARN-810, Brilanestrant) is a non-steroidal, orally bioavailable selective estrogen receptor degrader (SERD) with IC50 of 0.7 nM (ER-α degradation).
-
OBHSA
OBHSA（Oxabicycloheptane sulfonamide） is a novel selective estrogen receptor depressant (SERD) that can be used to study breast cancer.
-
Ralaniten
Ralaniten (EPI-506) is a novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer.
